The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.
Introduction
B-type natriuretic peptide (BNP) is a peptide hormone derived from atrial and ventricular cardiomyocytes [1] [2] [3] . Circulating plasma BNP levels have been well documented to be elevated in conditions characterized by various cardiac overloads [3] [4] [5] [6] [7] .
BNP activation reflects hemodynamic alterations and left ventricular dysfunction. The plasma BNP level thus provides prognostic information and is an important clinical tool [1, [8] [9] [10] . Atrial fibrillation (AF) causes ventricular hemodynamic alterations as well as atrial overload, and the plasma BNP level has also been reported to be increased in patients with AF [11] , even after controlling for demographic and clinical variables [12] . Conversely, cardioversion from AF to sinus rhythm decreased the plasma BNP level [13] [14] [15] .
AF is a common complication of hypertrophic cardiomyopathy (HCM), with an incidence ranging between 10 and 40% [16] [17] [18] [19] . AF causes deterioration in hemodynamic conditions, progression of heart failure and increased risk of thromboembolism in HCM [20, 21] . Treatment of association of paroxysmal AF (PAF) usually requires anticoagulant and/or antithrombotic therapy. The opportunity for detection of PAF is thought to be low in nonobstructive HCM patients compared 3 BNP, HCM and Atrial Fibrillation with obstructive HCM patients or HCM patients with heart failure, since the latter two types of patients require extensive treatment and frequent examination. From these considerations, even in nonobstructive HCM patients in the early phase of HCM, detection of PAF at an early time is quite important with respect to choosing a treatment strategy.
Based on these reported findings, we hypothesized that the plasma BNP level would be elevated in HCM patients, including nonobstructive HCM patients, with PAF compared to those with normal sinus rhythm (NSR). There are, however, no studies that measured plasma BNP levels in nonobstructive HCM patients in connection with AF. Accordingly, we determined plasma BNP levels in nonobstructive HCM patients and compared the values among nonobstructive HCM patients with NSR, those with PAF and those with chronic AF (CAF). showed stable conditions for at least 1 year after the plasma BNP measurements.
Patients and methods

Enrollment
Blood sampling
As stated above, blood sampling was performed during NSR within 3 months after an AF episode in PAF patients and the time of enrollment in CAF and NSR patients. 
Echocardiographic Measurements
Transthoracic M-mode, two-dimensional and Doppler echocardiography were performed using Toshiba SSA390A equipment (Toshiba Medical Systems, Tokyo, Japan) on the day of plasma BNP measurements or within 2 weeks after plasma BNP measurements. All examinations were performed by 2 medical technologists who were experienced experts in echocardiographic measurements and not aware of the clinical background of the patients. Echocardiographic recordings were performed in the long-axis parasternal plane and in the apical four-and two-chamber plane.
BNP, HCM and Atrial Fibrillation
Measurements were made according to the guidelines laid down by the American Society of Echocardiography [26] . The left atrial dimension (LAD) and left ventricular end-diastolic (LVEdD) and end-systolic dimension (LVEsD) were assessed by M-mode echocardiography in a standard fashion. LV hypertrophy was determined with two-dimensional echocardiographic recordings according to established criteria [27] . The greatest thickness measured at any site in the LV wall was considered to represent maximal LV wall thickness [16] . Peak instantaneous LV outflow gradient was estimated under basal conditions with continuous-wave Doppler [28] . Diagnosis of HCM was based on echocardiographic features of a hypertrophied, non-dilated LV in the absence of other cardiac or systemic diseases that cause cardiac hypertrophy [19, 29] .
Statistics
Because the distribution pattern of plasma BNP values did not appear to be normal, and the values were considerably shifted to one side, the values were transformed into a common logarithm (LogBNP) [30] . Data are expressed as mean±SD range. The t-test or Mann-Whitney U test was used to compare data between the 2 groups when appropriate. We employed one-way analysis of variance (ANOVA) for comparison 9 BNP, HCM and Atrial Fibrillation of 3 groups' data. Bonferroni's post-hoc t-test was also used to assess the differences of data between any 2 of the CAF, PAF and NSR groups. Area under the curve (AUC) and optimum cutoff level of each factor were determined by analyses of receiver operating characteristic curves (ROC curves). In ROC curves, when various cutoff values were selected, the relationship between the values of (sensitivity) and
(1-specificity) were plotted. The optimum cutoff was determined as the value that maximized the likelihood ratio (LR) obtained using the formula: LR = (sensitivity)/(1 -specificity) [31] . In other words, diagrammatically, the optimum cutoff can be chosen as the value that minimizes the distance from the upper left corner of the plot frame. The 95% confidence intervals for sensitivity and specificity were obtained using an appropriate program for a small number of cases that employs the relationship between inverse F-distribution, inverse beta function and binomial to get the "exact" binomial confidence interval [32, 33] . In patients with PAF and NSR, stepwise linear regression analysis was also performed with BNP as the dependent variable. Independent variables enrolled were association with PAF, age, gender, echocardiographic indices (LAD, LVEdD, LVEsD), drugs used, and association with diabetes mellitus. A p value of < 0.05 was considered significant.
Results
Plasma BNP levels
The PAF group showed significantly higher plasma BNP levels than the NSR group 
Relationship of plasma BNP level with echocardiographic indices
Plasma LogBNP level was significantly correlated with LAD (r=0.47, p<0.0001).
There were, however, no significant differences in LAD between the PAF group (43.4±10.4 mm) and the NSR group (39.9±4.9 mm), and therefore no significant AUC was obtained in the ROC analysis. There was no significant correlation between plasma LogBNP level and LVEdD or LVEsD, and no significant differences in either of these dimensions between the PAF and NSR groups.
Drugs
There were no significant differences in plasma LogBNP levels between patients with compared to without drug treatment in the whole set of patients or in any sub-group of patients.
Multivariate Analysis
The results of stepwise multiple linear regression analysis are shown in 
Discussion
The present study revealed that patients with PAF showed significantly higher plasma BNP levels than patients with NSR. ROC curve analysis revealed that plasma BNP level was clinically useful to identify HCM patients at risk for PAF.
The present results showed that plasma BNP levels were elevated even in nonobstructive HCM patients with NSR. Similar plasma BNP levels have been reported in nonobstructive HCM with NSR [34] . Another study observed similar plasma BNP levels in HCM patients of NYHA functional class I [35] . These reported results were in good agreement with the present results. Markedly elevated plasma BNP levels have been demonstrated in obstructive HCM and HCM with heart failure compared to uncomplicated nonobstructive HCM [34, 35] . These lines of evidence indicate that to examine the effects of AF on plasma BNP levels in HCM patients, it is essential to consider underlying pathological hemodynamic overload conditions. The present study therefore excluded HCM patients with LV obstructive condition, heart 13 BNP, HCM and Atrial Fibrillation failure or decreased LVEF and focused on identification of nonobstructive HCM patients with PAF. The fact that the basal data were identical with reported results indicated that the present analytical methods were valid.
The present results demonstrated that plasma BNP level was associated with AF.
Increased plasma BNP level in patients with lone AF has recently been demonstrated [36] . Moreover, PAF patients without any structural heart disease have also been
shown to exhibit increases in plasma BNP levels [37] . Our finding that plasma BNP levels were elevated, with mean values in decreasing order for CAF, PAF and NSR, were completely in agreement with these recently reported results.
The present study indicated that plasma BNP level may provide considerable information for distinguishing the PAF group from the NSR group. Although the present study did not find significant differences in LAD between nonobstructive HCM patients with PAF and those with NSR, there are reports of the detection of PAF patients with HCM using other markers such us echocardiographic measurements and 12-lead electrocardiographic findings [38] [39] [40] . In conclusion, the present study indicated that plasma BNP level is clinically useful for the identification of HCM patients who have a risk of PAF. Receiver operating characteristic curves of logarithmic transformed plasma BNP level (LogBNP) for distinguishing paroxysmal AF (PAF) group from normal sinus rhythm (NSR) group. AUC, area under the curve.
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